![The sights of the Paris Air Show Day 2 [PHOTOS]](https://breakingdefense.com/wp-content/uploads/sites/3/2025/06/IMG_1837-scaled-e1750181568851.jpg?#)
![An FCAS fracas and Embraer’s European embrace: Paris Air Show Day 2 [Video]](https://breakingdefense.com/wp-content/uploads/sites/3/2025/06/IMG_3682-e1750159767304.jpg?#)
![[Updated] U.S. Air Force Mobilizes F-22s and F-35s as Situation in Middle East Escalates](https://theaviationist.com/wp-content/uploads/2025/06/F-22_F-35_CENTCOM-top.jpg)
Neuropsychiatry biotech Draig Therapeutics hatches with red-hot $140M series A
A new biotech has come roaring to life in Wales with a $140 million series A and a lead candidate ready for phase 2 trials in major depressive disorder. Draig Therapeutics has emerged from a partnership between Cardiff University’s Medicine Discovery Institute and SV Health Investors to tackle unmet needs in neuropsychiatry.
A new biotech has come roaring to life in Wales with a $140 million series A and a lead candidate ready for phase 2 trials in major depressive disorder. Draig Therapeutics has emerged from a partnership between Cardiff University’s Medicine Discovery Institute and SV Health Investors to tackle unmet needs in neuropsychiatry.
